199 related articles for article (PubMed ID: 29635080)
1. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review.
Thiebaut M; Launay D; Rivière S; Mahévas T; Bellakhal S; Hachulla E; Fain O; Mekinian A
Autoimmun Rev; 2018 Jun; 17(6):582-587. PubMed ID: 29635080
[TBL] [Abstract][Full Text] [Related]
2. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
3. Rituximab treatment for systemic sclerosis-associated interstitial lung disease: a case series of 13 patients.
Morgan K; Woollard C; Beinart D; Host LV; Roddy J
Intern Med J; 2023 Jul; 53(7):1147-1153. PubMed ID: 35670218
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Bosello SL; De Luca G; Rucco M; Berardi G; Falcione M; Danza FM; Pirronti T; Ferraccioli G
Semin Arthritis Rheum; 2015 Feb; 44(4):428-36. PubMed ID: 25300701
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis-related interstitial lung diseases: a retrospective, observational cohort study.
Yılmaz DD; Borekci S; Musellim B
Clin Rheumatol; 2021 Oct; 40(10):4071-4079. PubMed ID: 34056665
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
Goswami RP; Ray A; Chatterjee M; Mukherjee A; Sircar G; Ghosh P
Rheumatology (Oxford); 2021 Feb; 60(2):557-567. PubMed ID: 33164098
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.
Elhai M; Boubaya M; Distler O; Smith V; Matucci-Cerinic M; Alegre Sancho JJ; Truchetet ME; Braun-Moscovici Y; Iannone F; Novikov PI; Lescoat A; Siegert E; Castellví I; Airó P; Vettori S; De Langhe E; Hachulla E; Erler A; Ananieva L; Krusche M; López-Longo FJ; Distler JHW; Hunzelmann N; Hoffmann-Vold AM; Riccieri V; Hsu VM; Pozzi MR; Ancuta C; Rosato E; Mihai C; Kuwana M; Saketkoo LA; Chizzolini C; Hesselstrand R; Ullman S; Yavuz S; Rednic S; Caimmi C; Bloch-Queyrat C; Allanore Y;
Ann Rheum Dis; 2019 Jul; 78(7):979-987. PubMed ID: 30967395
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis.
Moradzadeh M; Aghaei M; Mehrbakhsh Z; Arab-Bafrani Z; Abdollahi N
Clin Rheumatol; 2021 Oct; 40(10):3897-3918. PubMed ID: 33796953
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis.
Tang R; Yu J; Shi Y; Zou P; Zeng Z; Tang B; Wang Y; Ling G; Luo M; Xiao R
Int Immunopharmacol; 2020 Jun; 83():106389. PubMed ID: 32172205
[TBL] [Abstract][Full Text] [Related]
12. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Paliogianni F; Sirinian C; Yiannopoulos G; Andonopoulos AP
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S17-22. PubMed ID: 22244622
[TBL] [Abstract][Full Text] [Related]
13. Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels.
Kuzumi A; Ebata S; Fukasawa T; Matsuda KM; Kotani H; Yoshizaki-Ogawa A; Sato S; Yoshizaki A
JAMA Dermatol; 2023 Apr; 159(4):374-383. PubMed ID: 36790794
[TBL] [Abstract][Full Text] [Related]
14. Effects of rituximab in connective tissue disorders related interstitial lung disease.
Lepri G; Avouac J; Airò P; Anguita Santos F; Bellando-Randone S; Blagojevic J; Garcia Hernàndez F; Gonzalez Nieto JA; Guiducci S; Jordan S; Limaye V; Maurer B; Selva-O'Callaghan A; Riccieri V; Distler O; Matucci-Cerinic M; Allanore Y
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):181-185. PubMed ID: 27749242
[TBL] [Abstract][Full Text] [Related]
15. Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature.
Yarkan Tuğsal H; Zengin B; Kenar G; Önen F; Birlik M
Int J Rheum Dis; 2022 Jul; 25(7):755-768. PubMed ID: 35535670
[TBL] [Abstract][Full Text] [Related]
16. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Yoshizaki-Ogawa A; Asano Y; Kashiwabara K; Oba K; Sato S
J Dermatol; 2022 Jan; 49(1):179-183. PubMed ID: 34661314
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
[TBL] [Abstract][Full Text] [Related]
18. Role of rituximab in the treatment of systemic sclerosis: A literature review.
Yoshifuji H; Yomono K; Yamano Y; Kondoh Y; Yasuoka H
Mod Rheumatol; 2023 Nov; 33(6):1068-1077. PubMed ID: 37053127
[TBL] [Abstract][Full Text] [Related]
19. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center.
Vilela VS; Maretti GB; Gama LM; Costa CH; Rufino RL; Levy RA
Rev Bras Reumatol Engl Ed; 2016; 56(5):458-463. PubMed ID: 27692396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
